ORGANOPlus recreates the human body environment with human and patient-derived cells and organ-on-a-chip technology, and combines the resulting data with AI to develop a next-generation AI validation platform that improves drug efficacy, overcomes resistance and refines drug properties.
AI is accelerating the discovery of drug candidates, but validating how they actually respond in the human body remains a critical challenge.
Flat 2D cell cultures alone cannot fully recreate the three-dimensional structure of human tissue or the complex interactions between cells.
Because of biological differences between animals and humans, experimental results do not always match how drugs actually respond in the human body.
Organoid models reflect the characteristics of human tissue, so managing variability in culture conditions and between models is key to consistent data.
Expanding the use of human-mimetic technology in drug development requires standardized experimental data and reliable validation.
Throughout drug development, ORGANOPlus validates candidate responses with human-derived models and data, supporting decisions you can trust.
AI-driven exploration and prediction discover and optimize drug candidates.
Human and patient-derived organ-on-a-chip models evaluate drug responses and deliver human-derived validation data.
Human-derived validation data assesses each candidate’s development potential and supports the next development decision.
We are building an integrated platform that connects human-derived disease models and standardized validation data with AI, supporting human-response evaluation of drug candidates and data-driven decisions.
Human and patient-derived disease models
Standardized validation data built on SOP/QC
A next-generation drug validation platform linking human-derived validation data with AI prediction
Recreating the tumor microenvironment (TME) of cold and hot tumors with patient-derived tumor and immune cells to evaluate responses to anticancer and immuno-oncology candidates such as ADC, CAR-T and T-cell engagers.
Learn more
Recreating intestinal villi and the gut–microbiome microenvironment to evaluate barrier function, drug absorption, strain adhesion and survival, and IBD and Crohn’s disease models.
Learn more
From indication and modality to patient cohorts and multi-organ linkage (MAXORGAN™), we select the models and readouts you need.
Learn more
Built on standardized test procedures and quality control, we quantify drug response data and deliver the analysis you need for decisions.
Learn moreChuncheon, Gangwon-do
Gangnam-gu, Seoul
European business hub
ORGANOPlus Participates in 2026 SMART AGRITECH: GLOBAL NETWORKING DAY
ORGANOPlus joined the 2026 SMART AGRITECH: GLOBAL NETWORKING DAY to engage with investors and global partners on commercialization and international expansion. The event also highlighted the company’s growing…
[INVITATION]AFPRO 2026 Invitation(Booth 5001)
ORGANOPlus will participate in AFPRO 2026 at COEX, Seoul, from July 15 to 17. Visit us at Hall C, Booth 5001 to discover VILLIORGAN™, our AI-powered animal biomimetic…
AFPRO 2026: ORGANOPlus to Unveil VILLIORGAN™ for AI-Driven Livestock ESG Innovation
ORGANOPlus will participate in AFPRO 2026, held from July 15 to 17 at COEX in Seoul. The company will showcase VILLIORGAN™, an AI-powered animal biomimetic platform designed to…
Top Prize (Minister of SMEs and Startups Award), 2026 Regional Innovation Start-up Demo Day
Selected for the TIPS General Track, Startup Growth Technology Development Program (Ministry of SMEs and Startups)
Seed investment secured (Super-Gap OI Investment Partnership)
